MS Speaks

From MedPage Today (September 14, 2014), "Masitinib shows positive signs in progressive MS," a report from the recent ACTRIMS/ECTRIMS meeting:


https://www.medpagetoday.com/meetingcoverage/ectrims/88613


Of special note is this part of the article:

[/size]The drug, which specifically downregulates mast cells and microglia, appeared to slow disability progression in people with primary progressive multiple sclerosis (PPMS) and non-active secondary progressive MS (SPMS) over 2 years, reported Patrick Vermersch, PhD, of University of Lille in France, at MS Virtual 2020, the joint ACTRIMS-ECTRIMS meeting.[/size]
[/size]Point estimates consistently supported efficacy, but not all were significant.[/color]
[/size]This is the first time that a drug targeting innate immune cells -- as opposed to targeting adaptive immune cells like B cells and T cells -- has shown positive results in PPMS and non-active SPMS, Vermersch noted.[/color]
[/size][/color]

[/size]Emphasis added. I have never before seen an MS drug that is reported as indicated for non-active SPMS.[/color]


[/size][size=78%]Masitinib was mentioned in this thread, in the post dated 11/21/14--and it seems it has been used up to now in veterinary practice:[/size]


https://msspeaks.createaforum.com/general-discussion/clinical-focus-in-ms-novel-approaches-to-progressive-disease/msg564/#msg564